# Repare Therapeutics (stock symbol: RPTX) Logo in transparent PNG and SVG formats

## Repare Therapeutics Logo large

### Repare Therapeutics Logo large Download PNG (35.95 KB)

![Repare Therapeutics Logo large Download PNG (35.95 KB)](/img/orig/RPTX_BIG-71c72c1d.png)

### Repare Therapeutics Logo large Download SVG (5.07 KB)

![Repare Therapeutics Logo large Download SVG (5.07 KB)](/img/orig/RPTX_BIG-49fd29fc.svg)

## Repare Therapeutics Logo icon format

### Repare Therapeutics Logo icon format Download PNG (30.49 KB)

![Repare Therapeutics Logo icon format Download PNG (30.49 KB)](/img/orig/RPTX-46ebc2b5.png)

### Repare Therapeutics Logo icon format Download SVG (2.92 KB)

![Repare Therapeutics Logo icon format Download SVG (2.92 KB)](/img/orig/RPTX-7c95b608.svg)

## Repare Therapeutics Logo large for dark backgrounds

### Repare Therapeutics Logo large for dark backgrounds Download PNG (21.45 KB)

![Repare Therapeutics Logo large for dark backgrounds Download PNG (21.45 KB)](/img/orig/RPTX_BIG.D-da264207.png)

### Repare Therapeutics Logo large for dark backgrounds Download SVG (4.63 KB)

![Repare Therapeutics Logo large for dark backgrounds Download SVG (4.63 KB)](/img/orig/RPTX_BIG.D-a299685f.svg)

## Repare Therapeutics Logo icon format for dark backgrounds

### Repare Therapeutics Logo icon format for dark backgrounds Download PNG (14.49 KB)

![Repare Therapeutics Logo icon format for dark backgrounds Download PNG (14.49 KB)](/img/orig/RPTX.D-81fb44cb.png)

### Repare Therapeutics Logo icon format for dark backgrounds Download SVG (2.43 KB)

![Repare Therapeutics Logo icon format for dark backgrounds Download SVG (2.43 KB)](/img/orig/RPTX.D-3fdd9f29.svg)

## About Repare Therapeutics

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

1. Website domain: reparerx.com
2. Employees: 168
3. Marketcap: $0.37 Billion USD


## Categories
- [x] ðŸ‡¨ðŸ‡¦ Canada
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
